Galux Shows Broadest Target Coverage in Comparative De Novo Antibody Design Study
Galux, a South Korean biotechnology company pioneering AI-driven protein therapeutics design, announced comparative research results showing that its AI protein design platform, GaluxDesign, achieved the broadest target coverage across nine publicly comparable targets selected from recent de novo antibody design preprints.
Galux Raises $29M Series B to Advance AI-Driven Protein Design for Drug Discovery
Galux, a South Korea-based biotech pioneering AI-driven protein therapeutics design, today announced the successful completion of a $29 million (KRW 42 billion) Series B financing. With this round, the company’s total capital raised reaches $47 million (KRW 68 billion).
Galux Announces Research Agreement with Boehringer Ingelheim to Advance AI-Driven Protein Design
Galux, a South Korean biotech pioneering AI-driven protein therapeutics discovery, announced that it has signed a research agreement with Boehringer Ingelheim to jointly explore the application of artificial intelligence (AI) in precision protein design for therapeutic development. The goal is to evaluate how AI can be leveraged to design purpose-specific protein molecules that meet precise scientific and translational needs, where conventional approaches face limitations.
Galux Achieves Breakthrough by Delivering High-Affinity De Novo Antibodies from Only 50 AI Designs, Marking a New Era in Precision Protein Design
Galux, a South Korean biotech pioneering AI-driven protein therapeutics design, announced new experimental findings demonstrating that its AI protein design platform, GaluxDesign, can reliably generate high-affinity antibodies from minimal design sets, signaling a meaningful shift in how therapeutic antibodies can be discovered.
